BioSpace News Archive

On June 23, 2022, the World Health Organization Director General convened its International Health Regulations Emergency Committee to discuss the multi-country outbreak of monkeypox.

Today, the U.S. Food and Drug Administration issued a proposed rule titled, “Nonprescription Drug Product with an Additional Condition for Nonprescription Use,” which is intended to broaden the range of marketed nonprescription drugs available to consumers, empowering them to self-treat certain common conditions and improving public health.

As part of its expansion of radiation shielding solutions in the Industrial segment for radiopharmaceutical manufacturing, Veritas Medical Solutions recently partnered with NorthStar Medical Radioisotopes to construct a radiation shielded facility for the manufacture of concentrated molybdenum-99.

A team of researchers with the Illinois‐Express Quantum Network have successfully deployed a long-distance quantum network between two U.S. Department of Energy laboratories using local fiber optics.

Paradigm Biopharmaceuticals Ltd (ASX: PAR) (“Paradigm” or “the Company”), a clinical-stage biopharmaceutical company focused on repurposing existing molecules for new indications with unmet clinical needs, appointed experienced pharmaceutical industry executive Marco Polizzi as its full-time Chief Executive Officer (CEO), effective July 1, 2022.

DBMR released a report titled “Hemostats Market” which delivers detailed overview of the Hemostats market in terms of market segmentation by type, route of administration, end-user, and by region.

Centogene N.V., the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, announced the voting results of the Company’s Annual General Meeting.

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), today announced data presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 that took place June 22-26 in London, United Kingdom.

Kezar Life Sciences, Inc. (Nasdaq: KZR), today reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with active lupus nephritis (LN).

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection.